Analysis Of Transcatheter Arterial Embolization 106 Cases Of Hepatocellular Carcinoma Efficacy And Prognostic Factors

Objective: To investigate the survival time and prognostic factors of TACEtherapy for hepatocellular carcinoma in order to improve the efficacy by takingappropriate pre-treatment, and summarize the complications of the therapy inorder to evaluate the safety of TACE therapy for hepatocellular carcinoma.Methods: A retrospective analysis was carried out on the clinical data of106patients with unresectable hepatocellular carcinoma underwent TACE therapy inthe People’s Hospital of Guangxi Zhuang Autonomous Region from March2009to March2011.13factors might be associated with the survival time werescreened out for univariate analysis by using Kaplan-Meier method andLog-rank test and for multivariate analysis by using COX proportional hazardmodel.Results: The1-,2-and3-year survival rates in treatment of hepatocellularcarcinoma were39.78%,24.73%and16.13%, respectively. The1-,2-and3-year survival rates of small hepatocellular carcinoma less than5cm were76.12%,56.23%and44.35%, respectively. The1-,2-and3-year survival ratesof small hepatocellular carcinoma larger than5cm were29.41%,14.71%and5.88%, respectively. Among13univariate factors might be associated with thesurvival time, ten factors were statistically significant, including liver functionChild-Pugh classification, with or without cirrhosis, diameter of tumor, numberof tumors, clear or unclear tumor boundary, whether the tumor close to greatvessels, TACE times, with or without PEI, whether combined with othertreatments, and with or without tumor recurrence. There were four multivariatefactors associated with the survival rate of hepatocellular carcinoma, including liver function Child-Pugh classification, diameter of tumor, TACE times, andwhether combined with other treatments. The occurrence rate of severecomplications after TACE was3.65％, and death rate related to theinterventional treatment was0.00%.Conclusion: TACE therapy of hepatocellular carcinoma is a minimally invasivetreatment with a better efficacy, resulting in a greater survival rate for tumorssmaller than5cm than those larger than5cm. It is an ideal treatment methodfor patients with hepatocellular carcinoma cannot or are inappropriate forsurgical treatment. The independent prognostic factors involved in theintervention treatment of primary liver cancer include liver function Child-Pughclassification, diameter of tumor, TACE times, and whether combined withother treatments. Selection of appropriate treatment object before the treatment,reasonable control of indications for treatment, active improvement of patient’sliver function, and multiple TACE therapy combined with other treatmentmethods can get better benefits for patients. TACE therapy has a low incidenceof serious complications, which is similar with RFA and MicrowareCoagulation Therapy. Grasp the indication of TACE and use of standardizedmeasures of intervention therapy are essential for preventing and reducing theincidence of the serious complications．...